Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia

M.W.M. Kühn, E. Song, Z. Feng, A. Sinha, C.W. Chen, A.J. Deshpande, M. Cusan, N. Farnoud, A. Mupo, Carolyn Grove, R. Koche, J.E. Bradner, E. De Stanchina, G.S. Vassiliou, T. Hoshii, S.A. Armstrong

    Research output: Contribution to journalArticle

    70 Citations (Scopus)

    Abstract

    © 2016 American Association for Cancer Research.Homeobox (HOX) proteins and the receptor tyrosine kinase FLT3 are frequently highly expressed and mutated in acute myeloid leukemia (AML). Aberrant HOX expression is found in nearly all AMLs that harbor a mutation in the Nucleophosmin (NPM1) gene, and FLT3 is concomitantly mutated in approximately 60% of these cases. Little is known about how mutant NPM1 (NPM1mut) cells maintain aberrant gene expression. Here, we demonstrate that the histone modifiers MLL1 and DOT1L control HOX and FLT3 expression and differentiation in NPM1mut AML. Using a CRISPR/Cas9 genome editing domain screen, we show NPM1mut AML to be exceptionally dependent on the menin binding site in MLL1. Pharmacologic small-molecule inhibition of the menin–MLL1 protein interaction had profound antileukemic activity in human and murine models of NPM1mut AML. Combined pharmacologic inhibition of menin–MLL1 and DOT1L resulted in dramatic suppression of HOX and FLT3 expression, induction of differentiation, and superior activity against NPM1mut leukemia. SIGNIFICANCE: MLL1 and DOT1L are chromatin regulators that control HOX, MEIS1, and FLT3 expression and are therapeutic targets in NPM1mut AML. Combinatorial small-molecule inhibition has synergistic on-target activity and constitutes a novel therapeutic concept for this common AML subtype.
    Original languageEnglish
    Pages (from-to)1166-1181
    JournalCancer Discovery
    Volume6
    Issue number10
    DOIs
    Publication statusPublished - 2016

    Fingerprint Dive into the research topics of 'Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia'. Together they form a unique fingerprint.

    Cite this